Signature Estate & Investment Advisors LLC Incyte Corp Transaction History

Signature Estate & Investment Advisors LLC

$4.32 Billion
Q3 2024

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 07, 2020	SELL	$63.18 - $85.97 $994,895 - $1.35 Million	-15,747 Closed	0 $0
Q4 2019 Oct 09, 2020	BUY	$73.04 - $95.72 $22,131 - $29,003	303 Added 1.96%	15,747 $1.38 Million
Q4 2019 Feb 06, 2020	SELL	$73.04 - $95.72 $147,029 - $192,684	-2,013 Reduced 11.53%	15,444 $0
Q3 2019 Oct 09, 2020	BUY	$72.82 - $86.52 $3,640 - $4,326	50 Added 0.29%	17,457 $1.3 Million
Q3 2019 Oct 31, 2019	BUY	$72.82 - $86.52 $68,814 - $81,761	945 Added 5.74%	17,407 $1.29 Million
Q2 2019 Oct 09, 2020	BUY	$73.52 - $88.7 $7,278 - $8,781	99 Added 0.61%	16,462 $1.4 Million
Q2 2019 Aug 01, 2019	BUY	$73.52 - $88.7 $214,531 - $258,826	2,918 Added 21.7%	16,363 $1.39 Million
Q1 2019 Oct 13, 2020	BUY	$63.56 - $88.17 $2,987 - $4,143	47 Added 0.35%	13,445 $1.16 Million
Q1 2019 May 01, 2019	BUY	$63.56 - $88.17 $851,576 - $1.18 Million	13,398 New	13,398 $1.15 Million

Others Institutions Holding INCY

# of Institutions

643

Shares Held

186M

Call Options Held

714K

Put Options Held

557K

View Full List

About INCYTE CORP

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $15.7B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

More about INCY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Signature Estate & Investment Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Signature Estate & Investment Advisors LLC with notifications on news.

Account